Antibody drug conjugates (ADCs) that bind to FLT3 protein and variantsthereof are described herein. FLT3 exhibitsa distinct and limited expression pattern in normal adult tissue(s), and isaberrantly expressed in the cancers listed in Table I. Consequently,the ADCs of the invention provide a therapeutic composition for the treatmentof cancer.